Is the div_老虎社区_美港股上老虎

2021-12-02

Is the dividend sustainable?

2 Ridiculously Cheap Dividend Stocks To Buy for 2022<blockquote>2022 年值得购买的 2 只极其便宜的股息股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603507041,"tweetId":"603507041","gmtCreate":1638421447621,"gmtModify":1638421563758,"author":{"id":3581831647982295,"idStr":"3581831647982295","authorId":3581831647982295,"authorIdStr":"3581831647982295","name":"MoonMoon","avatar":"https://static.tigerbbs.com/7abc88bf78bc4fd17d5085b308a74c4d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Is the dividend sustainable?</body></html>","htmlText":"<html><head></head><body>Is the dividend sustainable?</body></html>","text":"Is the dividend sustainable?","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603507041","repostId":1182613816,"repostType":4,"repost":{"id":"1182613816","kind":"news","pubTimestamp":1638415076,"share":"https://www.laohunote.com/m/news/1182613816?lang=zh_CN&edition=full","pubTime":"2021-12-02 11:17","market":"us","language":"en","title":"2 Ridiculously Cheap Dividend Stocks To Buy for 2022<blockquote>2022 年值得购买的 2 只极其便宜的股息股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1182613816","media":"Motley Fool","summary":"The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could ","content":"The&nbsp;S&amp;P 500had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.<blockquote>这个标普500周五经历了今年最糟糕的一天，因经济复苏可能出现新障碍的消息而下跌 900 点：奥密克戎，最新的 COVID-19 变种。</blockquote> For investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excellent decision. They can ensure that you're collecting a recurring stream of income you can use to help offset losses in your portfolio. And at best, they can boost your returns. Two dividend stocks that pay an above-average yield and are incredibly cheap right now are&nbsp;AbbVie(NYSE:ABBV)and&nbsp;ViacomCBS(NASDAQ:VIAC).<blockquote>对于希望摆脱这种波动并找到更多安全感的投资者来说，在投资组合中持有股息股票可能是一个绝佳的决定。他们可以确保你收集到一个经常性的收入流，你可以用它来帮助抵消你的投资组合的损失。充其量，它们可以提高你的回报。两只股息股票的收益率高于平均水平，而且目前价格极其便宜。艾伯维（纽约证券交易所代码：ABBV）和维亚康姆哥伦比亚广播公司（纳斯达克股票代码：VIAC）</blockquote> 1. AbbVie<blockquote>1.艾伯维</blockquote> AbbVie makes for an ideal buy-and-forget investment. The&nbsp;healthcare stock&nbsp;yields an impressive 4.8% right now -- well above the&nbsp;S&amp;P 500average of just 1.4%. And the dividend is well supported; in the past 12 months, the company has generated free cash flow of $21.7 billion, more than double the $9 billion in dividends it paid out during that time.<blockquote>艾伯维 (AbbVie) 是一项理想的买入即可忘记投资。医疗保健股目前的收益率高达 4.8%，远高于标普500平均只有1.4%。并且股息得到了很好的支持；在过去的12个月里，该公司产生了217亿美元的自由现金流，是当时支付的90亿美元股息的两倍多。</blockquote> When the company released its latest quarterly earnings results on Oct. 29, it reported sales of $14.3 billion, 11% higher than the year-ago period. The company also raised its guidance for a third time in 2021, anticipating that its adjusted diluted earnings per share will come in between $12.63 and $12.67 for the full year. That's well above the $5.64 in dividends that the company is paying out annually per share. TheDividend Aristocratalso raised its dividend by 8.5% in a hike that will come into effect next year.<blockquote>当该公司于 10 月 29 日发布最新季度财报时，销售额为 143 亿美元，比去年同期增长 11%。该公司还在 2021 年第三次上调了指引，预计全年调整后稀释每股收益将在 12.63 美元至 12.67 美元之间。这远高于该公司每年支付的每股 5.64 美元股息。这家股息贵族还将股息提高了 8.5%，并将于明年生效。</blockquote> While investors may be worried about the company's expiring patent on rhe&nbsp;umatoid arthritis drug Humira, AbbVie's management anticipates that newer drugs like Skyrizi and Rinvoq will generate long-term growth and make up for the inevitable decline in Humira's sales. Both drugs still have a long way to go. In just the latest quarter, they achieved combined sales of $1.2 billion in sales while Humira brought in more than $5.4 billion.<blockquote>虽然投资者可能担心该公司即将到期的rhe类风湿关节炎药物Humira的专利，但艾伯维管理层预计，Skyrizi和Rinvoq等新药将产生长期增长，并弥补Humira销售额不可避免的下降。这两种药物还有很长的路要走。仅在最近一个季度，他们的总销售额就达到了 12 亿美元，而 Humira 的销售额则超过了 54 亿美元。</blockquote> CEO Richard Gonzalez said, \"What we're basically trying to accomplish with the company is build a set of assets that could ultimately significantly replace Humira in the marketplace and be superior to Humira.\"<blockquote>首席执行官理查德·冈萨雷斯 (Richard Gonzalez) 表示：“我们与公司基本上要实现的目标是建立一套资产，最终可以在市场上显着取代修美乐，并优于修美乐。”</blockquote> Even if there's a dip in profitability, AbbVie has plenty of room to support its dividend. And with other pharma stocks like&nbsp;Pfizer,Merck, and&nbsp;Amgen&nbsp;trading at forward&nbsp;price-to-earnings(P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy.<blockquote>即使盈利能力下降，艾伯维也有足够的空间来支持其股息。以及其他制药股，例如辉瑞,默克，和安进艾伯维的远期市盈率 (P/E) 倍数超过 12，9 倍使该股看起来像是便宜货。</blockquote> 2. ViacomCBS<blockquote>2. 维亚康姆哥伦比亚广播公司</blockquote> Media and entertainment company ViacomCBS pays a dividend that currently yields right around 3% per year. While it's not as high as AbbVie's payout, the stock could more than make up for that with some possibly stronger gains. Viacom currently trades at a forward P/E of less than nine, which is dirt cheap as streaming stocks&nbsp;WaltDisney&nbsp;and&nbsp;Netflix&nbsp;trade at multiples of 35 and 62, respectively.<blockquote>媒体和娱乐公司 ViacomCBS 支付的股息目前每年收益率约为 3%。虽然它没有艾伯维的派息那么高，但该股可以通过一些可能更强劲的涨幅来弥补这一点。维亚康姆目前的远期市盈率不到 9，作为流媒体股票来说非常便宜华特迪士尼和网飞分别以 35 和 62 的倍数进行交易。</blockquote> One of the reasons investors aren't as bullish on ViacomCBS is that it still isn't a big rival to those streaming giants. At 47 million global streaming subscribers across its services (including Paramount+), ViacomCBS is nowhere near Netflix's tally of 214 million and has a long way to go in catching up to Disney at over 118 million.<blockquote>投资者不太看好维亚康姆哥伦比亚广播公司的原因之一是，它仍然不是这些流媒体巨头的主要竞争对手。维亚康姆哥伦比亚广播公司（ViacomCBS）在其服务（包括派拉蒙+）拥有 4700 万全球流媒体用户，远未达到 Netflix 的 2.14 亿用户，距离赶上迪士尼超过 1.18 亿的用户还有很长的路要走。</blockquote> Plus, ViacomCBS's streaming service isn't even the biggest part of its business. In the latest quarter, its advertising, affiliate, and licensing segments together contributed the vast majority of the company's revenue -- about $5.5 billion in all. However, this latest quarter marked the first time that its global streaming revenue surpassed $1 billion. And with revenue growth of 72% over the year-ago period, streaming is by far the company's fastest-growing segment.<blockquote>此外，维亚康姆哥伦比亚广播公司的流媒体服务甚至不是其业务的最大部分。在最近一个季度，其广告、联盟和授权部门共同贡献了该公司的绝大部分收入——总计约55亿美元。然而，最近一个季度标志着其全球流媒体收入首次超过10亿美元。流媒体业务的收入同比增长了 72%，是该公司迄今为止增长最快的领域。</blockquote> Although it may not be as popular as its bigger-name rivals, ViacomCBS is posting some strong results of late and it could be an&nbsp;attractive contrarian betto take. Plus, its dividend makes it an even better buy.<blockquote>尽管它可能不像其知名竞争对手那样受欢迎，但维亚康姆哥伦比亚广播公司最近公布了一些强劲的业绩，这可能是一个有吸引力的逆向投资。此外，它的股息使其更值得购买。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Ridiculously Cheap Dividend Stocks To Buy for 2022<blockquote>2022 年值得购买的 2 只极其便宜的股息股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Ridiculously Cheap Dividend Stocks To Buy for 2022<blockquote>2022 年值得购买的 2 只极其便宜的股息股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-12-02 11:17\n\n</h4>\n</header>\n<article>\nThe&nbsp;S&amp;P 500had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.<blockquote>这个标普500周五经历了今年最糟糕的一天，因经济复苏可能出现新障碍的消息而下跌 900 点：奥密克戎，最新的 COVID-19 变种。</blockquote> For investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excellent decision. They can ensure that you're collecting a recurring stream of income you can use to help offset losses in your portfolio. And at best, they can boost your returns. Two dividend stocks that pay an above-average yield and are incredibly cheap right now are&nbsp;AbbVie(NYSE:ABBV)and&nbsp;ViacomCBS(NASDAQ:VIAC).<blockquote>对于希望摆脱这种波动并找到更多安全感的投资者来说，在投资组合中持有股息股票可能是一个绝佳的决定。他们可以确保你收集到一个经常性的收入流，你可以用它来帮助抵消你的投资组合的损失。充其量，它们可以提高你的回报。两只股息股票的收益率高于平均水平，而且目前价格极其便宜。艾伯维（纽约证券交易所代码：ABBV）和维亚康姆哥伦比亚广播公司（纳斯达克股票代码：VIAC）</blockquote> 1. AbbVie<blockquote>1.艾伯维</blockquote> AbbVie makes for an ideal buy-and-forget investment. The&nbsp;healthcare stock&nbsp;yields an impressive 4.8% right now -- well above the&nbsp;S&amp;P 500average of just 1.4%. And the dividend is well supported; in the past 12 months, the company has generated free cash flow of $21.7 billion, more than double the $9 billion in dividends it paid out during that time.<blockquote>艾伯维 (AbbVie) 是一项理想的买入即可忘记投资。医疗保健股目前的收益率高达 4.8%，远高于标普500平均只有1.4%。并且股息得到了很好的支持；在过去的12个月里，该公司产生了217亿美元的自由现金流，是当时支付的90亿美元股息的两倍多。</blockquote> When the company released its latest quarterly earnings results on Oct. 29, it reported sales of $14.3 billion, 11% higher than the year-ago period. The company also raised its guidance for a third time in 2021, anticipating that its adjusted diluted earnings per share will come in between $12.63 and $12.67 for the full year. That's well above the $5.64 in dividends that the company is paying out annually per share. TheDividend Aristocratalso raised its dividend by 8.5% in a hike that will come into effect next year.<blockquote>当该公司于 10 月 29 日发布最新季度财报时，销售额为 143 亿美元，比去年同期增长 11%。该公司还在 2021 年第三次上调了指引，预计全年调整后稀释每股收益将在 12.63 美元至 12.67 美元之间。这远高于该公司每年支付的每股 5.64 美元股息。这家股息贵族还将股息提高了 8.5%，并将于明年生效。</blockquote> While investors may be worried about the company's expiring patent on rhe&nbsp;umatoid arthritis drug Humira, AbbVie's management anticipates that newer drugs like Skyrizi and Rinvoq will generate long-term growth and make up for the inevitable decline in Humira's sales. Both drugs still have a long way to go. In just the latest quarter, they achieved combined sales of $1.2 billion in sales while Humira brought in more than $5.4 billion.<blockquote>虽然投资者可能担心该公司即将到期的rhe类风湿关节炎药物Humira的专利，但艾伯维管理层预计，Skyrizi和Rinvoq等新药将产生长期增长，并弥补Humira销售额不可避免的下降。这两种药物还有很长的路要走。仅在最近一个季度，他们的总销售额就达到了 12 亿美元，而 Humira 的销售额则超过了 54 亿美元。</blockquote> CEO Richard Gonzalez said, \"What we're basically trying to accomplish with the company is build a set of assets that could ultimately significantly replace Humira in the marketplace and be superior to Humira.\"<blockquote>首席执行官理查德·冈萨雷斯 (Richard Gonzalez) 表示：“我们与公司基本上要实现的目标是建立一套资产，最终可以在市场上显着取代修美乐，并优于修美乐。”</blockquote> Even if there's a dip in profitability, AbbVie has plenty of room to support its dividend. And with other pharma stocks like&nbsp;Pfizer,Merck, and&nbsp;Amgen&nbsp;trading at forward&nbsp;price-to-earnings(P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy.<blockquote>即使盈利能力下降，艾伯维也有足够的空间来支持其股息。以及其他制药股，例如辉瑞,默克，和安进艾伯维的远期市盈率 (P/E) 倍数超过 12，9 倍使该股看起来像是便宜货。</blockquote> 2. ViacomCBS<blockquote>2. 维亚康姆哥伦比亚广播公司</blockquote> Media and entertainment company ViacomCBS pays a dividend that currently yields right around 3% per year. While it's not as high as AbbVie's payout, the stock could more than make up for that with some possibly stronger gains. Viacom currently trades at a forward P/E of less than nine, which is dirt cheap as streaming stocks&nbsp;WaltDisney&nbsp;and&nbsp;Netflix&nbsp;trade at multiples of 35 and 62, respectively.<blockquote>媒体和娱乐公司 ViacomCBS 支付的股息目前每年收益率约为 3%。虽然它没有艾伯维的派息那么高，但该股可以通过一些可能更强劲的涨幅来弥补这一点。维亚康姆目前的远期市盈率不到 9，作为流媒体股票来说非常便宜华特迪士尼和网飞分别以 35 和 62 的倍数进行交易。</blockquote> One of the reasons investors aren't as bullish on ViacomCBS is that it still isn't a big rival to those streaming giants. At 47 million global streaming subscribers across its services (including Paramount+), ViacomCBS is nowhere near Netflix's tally of 214 million and has a long way to go in catching up to Disney at over 118 million.<blockquote>投资者不太看好维亚康姆哥伦比亚广播公司的原因之一是，它仍然不是这些流媒体巨头的主要竞争对手。维亚康姆哥伦比亚广播公司（ViacomCBS）在其服务（包括派拉蒙+）拥有 4700 万全球流媒体用户，远未达到 Netflix 的 2.14 亿用户，距离赶上迪士尼超过 1.18 亿的用户还有很长的路要走。</blockquote> Plus, ViacomCBS's streaming service isn't even the biggest part of its business. In the latest quarter, its advertising, affiliate, and licensing segments together contributed the vast majority of the company's revenue -- about $5.5 billion in all. However, this latest quarter marked the first time that its global streaming revenue surpassed $1 billion. And with revenue growth of 72% over the year-ago period, streaming is by far the company's fastest-growing segment.<blockquote>此外，维亚康姆哥伦比亚广播公司的流媒体服务甚至不是其业务的最大部分。在最近一个季度，其广告、联盟和授权部门共同贡献了该公司的绝大部分收入——总计约55亿美元。然而，最近一个季度标志着其全球流媒体收入首次超过10亿美元。流媒体业务的收入同比增长了 72%，是该公司迄今为止增长最快的领域。</blockquote> Although it may not be as popular as its bigger-name rivals, ViacomCBS is posting some strong results of late and it could be an&nbsp;attractive contrarian betto take. Plus, its dividend makes it an even better buy.<blockquote>尽管它可能不像其知名竞争对手那样受欢迎，但维亚康姆哥伦比亚广播公司最近公布了一些强劲的业绩，这可能是一个有吸引力的逆向投资。此外，它的股息使其更值得购买。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182613816","content_text":"The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.\nFor investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excellent decision. They can ensure that you're collecting a recurring stream of income you can use to help offset losses in your portfolio. And at best, they can boost your returns. Two dividend stocks that pay an above-average yield and are incredibly cheap right now are AbbVie(NYSE:ABBV)and ViacomCBS(NASDAQ:VIAC).\n1. AbbVie\nAbbVie makes for an ideal buy-and-forget investment. The healthcare stock yields an impressive 4.8% right now -- well above the S&P 500average of just 1.4%. And the dividend is well supported; in the past 12 months, the company has generated free cash flow of $21.7 billion, more than double the $9 billion in dividends it paid out during that time.\nWhen the company released its latest quarterly earnings results on Oct. 29, it reported sales of $14.3 billion, 11% higher than the year-ago period. The company also raised its guidance for a third time in 2021, anticipating that its adjusted diluted earnings per share will come in between $12.63 and $12.67 for the full year. That's well above the $5.64 in dividends that the company is paying out annually per share. TheDividend Aristocratalso raised its dividend by 8.5% in a hike that will come into effect next year.\nWhile investors may be worried about the company's expiring patent on rhe umatoid arthritis drug Humira, AbbVie's management anticipates that newer drugs like Skyrizi and Rinvoq will generate long-term growth and make up for the inevitable decline in Humira's sales. Both drugs still have a long way to go. In just the latest quarter, they achieved combined sales of $1.2 billion in sales while Humira brought in more than $5.4 billion.\nCEO Richard Gonzalez said, \"What we're basically trying to accomplish with the company is build a set of assets that could ultimately significantly replace Humira in the marketplace and be superior to Humira.\"\nEven if there's a dip in profitability, AbbVie has plenty of room to support its dividend. And with other pharma stocks like Pfizer,Merck, and Amgen trading at forward price-to-earnings(P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy.\n2. ViacomCBS\nMedia and entertainment company ViacomCBS pays a dividend that currently yields right around 3% per year. While it's not as high as AbbVie's payout, the stock could more than make up for that with some possibly stronger gains. Viacom currently trades at a forward P/E of less than nine, which is dirt cheap as streaming stocks WaltDisney and Netflix trade at multiples of 35 and 62, respectively.\nOne of the reasons investors aren't as bullish on ViacomCBS is that it still isn't a big rival to those streaming giants. At 47 million global streaming subscribers across its services (including Paramount+), ViacomCBS is nowhere near Netflix's tally of 214 million and has a long way to go in catching up to Disney at over 118 million.\nPlus, ViacomCBS's streaming service isn't even the biggest part of its business. In the latest quarter, its advertising, affiliate, and licensing segments together contributed the vast majority of the company's revenue -- about $5.5 billion in all. However, this latest quarter marked the first time that its global streaming revenue surpassed $1 billion. And with revenue growth of 72% over the year-ago period, streaming is by far the company's fastest-growing segment.\nAlthough it may not be as popular as its bigger-name rivals, ViacomCBS is posting some strong results of late and it could be an attractive contrarian betto take. Plus, its dividend makes it an even better buy.","news_type":1,"symbols_score_info":{"VIAC":0.9,"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":1187,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603507041"}